Press Release - Company Data

Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder
Posted 2014-07-21 00:03NAI Editing
today announced that the U.S.

Avanir Pharmaceuticals Announces Completion of Patient Enrollment in Study of AVP-923 for the Treatment of Agitation in Patients with Alzheimer's Disease
Posted 2014-05-26 23:38NAI Editing
today announced completion of patient enrollment in the company's phase II, placebo controlled study testing AVP-923 for the treatment of agitation in Alzheimer's disease patients.

Avanir Pharmaceuticals Announces Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
Posted 2014-03-25 23:30NAI Editing
today announced that the U.S.

Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
Posted 2013-10-28 23:39NAI Editing
today announced preliminary financial information (unaudited) for the year ended September 30, 2013, in anticipation of the company's Investor Relations Day in

Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
Posted 2013-09-19 23:30NAI Editing
today announced the publication of a pharmacokinetic (PK) study of AVP-825, a novel Breath Powered device used to deliver sumatriptan powder intranasally for the treatment of acute migraine.

Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Posted 2013-09-06 02:56NAI Editing
today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd.

Avanir Pharmaceuticals Announces Publication of 'PRISM' Pseudobulbar Affect Registry Findings
Posted 2013-08-21 23:15NAI Editing
today announced the publication of the findings from the PRISM patient registry in PLOS ONE, an international, peer-reviewed, open-access medical journal.

Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Posted 2013-07-05 06:17NAI Editing
today announced that on July 2, 2013, the Company approved the grant of stock options to new employees to purchase 91,500 shares of common stock in the aggregate.

Avanir Pharmaceuticals and OptiNose Announce Development and Commercialization Agreement for a New Fast-Acting Investigational Product for the Treatment of Acute Migraine
Posted 2013-07-02 06:35NAI Editing
and OptiNose AS today announced that the companies have entered into an exclusive North American license agreement for the development and commercialization of OptiNose's novel Breath Powered™ intran

Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
Posted 2013-06-04 23:40NAI Editing
today announced that the U.S.